Mayo Clinic

Advancing PSP and CBD Research: CurePSP Announces Latest Pathway and Pipeline Grant Recipients

Retrieved on: 
Thursday, March 14, 2024
Diagnosis, Neuroscience, PSP, Mayo Clinic, Biomarker, University, CBD, University of Cambridge, Proteomics, Corticobasal degeneration, University of Edinburgh, UCLA, Medical device

NEW YORK, March 14, 2024 /PRNewswire/ -- CurePSP has awarded its latest Pathway and Pipeline Grants, totaling approximately $400,000.

Key Points: 
  • NEW YORK, March 14, 2024 /PRNewswire/ -- CurePSP has awarded its latest Pathway and Pipeline Grants, totaling approximately $400,000.
  • The studies will make progress in understanding the basic neurobiology of progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) and in developing biomarkers to improve diagnosis and treatment.
  • The newest Pipeline grants will fund two projects: "Blood-based Fingerprints of Neuroinflammation in People with PSP and CBD" by Dr. Maura Malpetti, and "Characterization of Plasma-derived Extracellular Vesicle Proteomics for Biomarker Development of PSP and CBD" by Dr. Yang You.
  • "There is a critical need to improve our understanding of PSP and CBD and to improve diagnosis, and these grants will help move the field forward."

PRECISIO BIOTIX THERAPEUTICS ANNOUNCES COLLABORATION WITH MAYO CLINIC

Retrieved on: 
Thursday, March 14, 2024
Enzyme, Health, Lysin, Education, Patient, Lung, Mayo Clinic, Research, Bacteria, AI, AMR, Infection, Genetically modified bacteria, Therapy, Engineering, Pharmaceutical industry

DOVER, Del., March 14, 2024 /PRNewswire/ -- Precisio Biotix Therapeutics ("Precisio") today announced it has entered into an agreement with Mayo Clinic. The collaboration will include co-development of novel precision antibacterials targeting indications prone to antimicrobial-resistant (AMR) infections.

Key Points: 
  • The announcement by Mark Engel, Precisio Biotix's Chairman and CEO, highlights another step by Precisio Biotix to advance novel precision biological antibacterials.
  • DOVER, Del., March 14, 2024 /PRNewswire/ -- Precisio Biotix Therapeutics ("Precisio") today announced it has entered into an agreement with Mayo Clinic.
  • Dr. Assaf Raz, VP of R&D, stated: "We are delighted to work with Mayo Clinic.
  • Mayo Clinic has a financial interest in the technology and will use any revenue it receives to support its patient care, education and research.

apoQlar enters into Collaboration with Mayo Clinic to Advance Patient Care with Extended Reality Technology

Retrieved on: 
Tuesday, March 12, 2024
XR, Education, VSI, Patient, Mayo Clinic, HIMSS, Health, Cancer, Environment

ORLANDO, Fla., March 12, 2024 /PRNewswire/ -- apoQlar, a pioneer in medical visualization technology, is excited to announce a collaboration with Mayo Clinic aimed at enhancing patient care through the innovative application of extended reality (XR) technology.

Key Points: 
  • ORLANDO, Fla., March 12, 2024 /PRNewswire/ -- apoQlar, a pioneer in medical visualization technology, is excited to announce a collaboration with Mayo Clinic aimed at enhancing patient care through the innovative application of extended reality (XR) technology.
  • Sirko Pelzl, CEO of apoQlar, shared his excitement about the collaboration, stating, "We aim to revolutionize patient care by incorporating cutting-edge XR technology into daily medical practices and workflows.
  • The use of XR technology in patient care is anticipated to offer extensive benefits, such as enhanced surgical planning, improved interdisciplinary team collaboration, and more effective patient education.
  • The collaboration will commence with a project dedicated to leveraging XR technology for developing personalized treatment plans within Mayo Clinic.

World Vaccine Congress Draws Leaders from Government, Science and Industry

Retrieved on: 
Monday, March 11, 2024
Convention center, Bee, Washington Convention Center, Congress, Walter, Global health, Mayo Clinic, Food and Drug Administration, Cancer, International, Science Advisory Board, World Health Organization, Immunization, Vaccination, Bangladesh Technical Education Board, Vaccine, Food, Pharmaceutical industry

WASHINGTON, March 11, 2024 /PRNewswire/ -- The world's top experts and policymakers, including government leaders, renown researchers and company executives driving vaccine development, will gather to discuss the latest progress in vaccines — from efforts to inoculate bees to a discussion of pathogens that could cause the next pandemic — at the World Vaccine Congress April 1-4.

Key Points: 
  • "We have assembled the world's foremost experts and policymakers in the field of vaccination for the 2024 World Vaccine Congress," said Dr. Gregory A. Poland, Director of Mayo Vaccine Research Group, Mayo Clinic and a member of the Science Advisory Board.
  • "This event represents an unparalleled opportunity for collaboration and innovation and promises to drive meaningful progress in global health.
  • It is a unique and massive forum for discovery and access to leaders across the field."
  • In-depth sessions also cover vaccine supply and logistics, veterinary vaccines, emerging diseases, and vaccine delivery.

Affluent Medical : Excellent valve performance at 1 year follow up and rising recognition of Epygon biomimetic mitral valve.

Retrieved on: 
Wednesday, March 13, 2024
Mitral regurgitation, Ticker, Aix-en-Provence, Doctor of Philosophy, MD, Overalls, Physiology, Hospital, Minerva, Risk, Tricuspid valve, Mayo Clinic, Clinical professor, Death, American College, Medtech, Mitral valve, Patient, Interventional cardiology

Affluent Medical : Excellent valve performance at 1 year follow up and rising recognition of Epygon biomimetic mitral valve.

Key Points: 
  • Affluent Medical : Excellent valve performance at 1 year follow up and rising recognition of Epygon biomimetic mitral valve.
  • The article summarizes the procedure and the follow up at 6 months, which showed continued good prosthetic performance.
  • Examination through a transesophageal echocardiogram revealed excellent valve performance, with neither mitral regurgitation nor paravalvular leak.
  • Mitral valve regurgitation is a serious and potentially fatal disease affecting 2% of the world's population, or approximately 160 million people.

Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Monday, March 11, 2024
Fast Track, ICT, ICV, Research, WM, Indolent lymphoma, XSCID, NHL, ASH, FDA, Birmingham School of Law, City, Cancer, DSM-IV codes, Mustang, Sale, Nature, Tocilizumab, GBM, Standard of care, Safety, Dexamethasone, Society, University, Mayo Clinic, Clinical professor, Translation, University of Washington, Foreign investment, Tumor microenvironment, Associate, CRS, Patient, Clinical trial, Disease, Survival, CFIUS, Cytokine release syndrome, Follicular lymphoma, Pharmaceutical industry

WORCESTER, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced financial results and recent corporate highlights for the full-year ended December 31, 2023.

Key Points: 
  • WORCESTER, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced financial results and recent corporate highlights for the full-year ended December 31, 2023.
  • Research and development expenses were $40.5 million for the year ended December 31, 2023, compared to $62.5 million for 2022.
  • 2023 and Recent Corporate Highlights:
    In July 2023, Mustang announced that it amended its previously announced asset purchase agreement with uBriGene (Boston) Biosciences Inc. (“uBriGene”) and closed the transaction.
  • In October 2023, Mustang completed a registered direct offering priced at-the-market for approximately $4.4 million in gross proceeds.

Autolus Therapeutics announces publication in Blood Cancer Journal

Retrieved on: 
Monday, March 11, 2024
TRBC1, Antibody, Mayo Clinic, Lymphoid leukemia, Thermo Fisher Scientific, TRBC, Bone marrow, Flow cytometry, Vaccine

LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a publication in Blood Cancer Journal entitled ‘Dual T-cell constant β chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry.’ 1

Key Points: 
  • LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a publication in Blood Cancer Journal entitled ‘Dual T-cell constant β chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry.’ 1
    Diagnosing leukemic T-cell malignancies poses challenges due to their resemblance to reactive T-cells.
  • In the paper published by Pedro Horna of Mayo Clinic in collaboration with Autolus, the authors introduce a unique approach for identifying T-cell neoplasms by flow cytometry1.
  • This method adopts the recently described monoclonal antibodies targeting TRBC1 and TRBC22, 3, to assess for TRBC-restriction as a surrogate of clonality.
  • The strategy mirrors the routine and broadly adopted analysis of kappa and lambda immunoglobulin chain restriction for the identification of B-cell malignancies.

Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024

Retrieved on: 
Thursday, March 7, 2024
PD, Research, Doctor of Philosophy, SVP, Cerebrospinal fluid, Conference, MJFF, Mayo Clinic, Clinical professor, Patient, CSF, Synucleinopathy, Pharmaceutical industry

UB-312 is the first active immunotherapy candidate to show reduction of pathological alpha-synuclein (aSyn) in cerebrospinal fluid (CSF) of PD patients.

Key Points: 
  • UB-312 is the first active immunotherapy candidate to show reduction of pathological alpha-synuclein (aSyn) in cerebrospinal fluid (CSF) of PD patients.
  • UB-312 is designed to target aggregated forms of aSyn, the toxic species that underlies PD and other synucleinopathies.
  • As part of the randomized, double-blind, placebo-controlled Phase 1 clinical trial, The Michael J.
  • “Currently, there are no treatments that address the underlying conditions of Parkinson’s, and we are very excited about this target engagement data.

Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights

Retrieved on: 
Tuesday, March 5, 2024
Research, FDA, Platinum, Exercise, ARID1A, Mayo Clinic, Ovarian cancer, Clinical professor, Cholangiocarcinoma, PIPE

Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, "2023 was an eventful year for Nuvectis as we continued to make important strides with our two clinical-stage drug candidates, NXP800 and NXP900.

Key Points: 
  • Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, "2023 was an eventful year for Nuvectis as we continued to make important strides with our two clinical-stage drug candidates, NXP800 and NXP900.
  • Cash, and cash equivalents were $19.1 million as of December 31, 2023, compared to $20.0 million as of December 31, 2022.
  • Net loss for the 2023 fiscal year included $4.7 million in non-cash stock-based compensation and $2.3 million in one-time non-recurring expenses.
  • Interest income was $0.6 million for the year ended December 31, 2023, compared to $0.1 million for the year ended December 31, 2022, an increase of $0.5 million.

Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024

Retrieved on: 
Tuesday, February 27, 2024
Master of Science, PD, Doctor of Philosophy, Medical school, GBA, Alpha-synuclein, Conference, EMBA, Parkinson's disease, Medical University of Innsbruck, Biomarker, Mayo Clinic, Multiple system atrophy, Patient, Dementia, Synucleinopathy, Development, DSM-IV codes, Lewy body, Biogen, Management

MALVERN, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced panel participation in the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024) , taking place in Lisbon, Portugal March 5-9, 2024.

Key Points: 
  • MALVERN, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced panel participation in the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024) , taking place in Lisbon, Portugal March 5-9, 2024.
  • Maria Maccecchini, PhD, Founder, President, and CEO of Annovis, will join a forum discussion focused on new approaches for alpha-synuclein (αSyn), LRKK2, and GBA pathologies.
  • Aggregated αSyn is the major constituent of Lewy bodies and a pathogenic hallmark of all synucleinopathies, including Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.
  • It is present in a number of other neurodegenerative diseases and is responsible for axonal impairment and synaptic degeneration.